This inventor holds 1 USPTO granted patent. Top assignee: The State University of New York. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Edward L Chan: Innovator in EGFR-Related Cancer Research
Introduction
Edward L Chan is a notable inventor based in Mount Sinai, NY (US). He has made significant contributions to the field of cancer research, particularly in understanding the role of the epidermal growth factor receptor (EGFR) in head and neck cancers. His work has implications for treatment selection and predicting clinical outcomes for patients.
Latest Patents
Edward L Chan holds a patent for "EGFR-related polypeptides and methods of use." This patent describes truncated EGF receptor polypeptides, nucleic acids encoding them, and methods for using these innovations to select treatment methods for EGFR-related cancers. The research highlights that high EGFR expression and phosphorylated EGFR are indicators of poor survival in head and neck cancer patients, although they do not correlate with advanced stage disease. His studies involved analyzing EGFR phosphorylation, expression, and mutations in 60 primary head and neck tumors, revealing that tumors with truncated or activated EGFR tend to have higher tumor and nodal stages.
Career Highlights
Edward L Chan is affiliated with The State University of New York, where he continues to advance his research in cancer biology. His work has been instrumental in identifying clinical biological correlates that improve the accuracy of cancer treatment predictions.
Collaborations
Edward collaborates with James McNeel Keller, contributing to the advancement of knowledge in the field of cancer research.
Conclusion
Edward L Chan's innovative work in EGFR-related cancer research exemplifies the critical intersection of science and technology in improving patient outcomes. His contributions are vital in the ongoing fight against cancer.